How to Vet a Placental Stem Cell Products Supplier for Your Practice

The regenerative medicine sector has expanded at a rapid pace, with the global market valued at approximately USD 35.85 billion in 2024 and projected to reach USD 169.55 billion by 2034, a compound annual growth rate exceeding 16 percent [5]. Perinatal and placental-derived biologics represent a substantial share of that growth, driven by clinician demand for allograft options in orthopedic, wound care, and aesthetic applications. Regulatory oversight, however, has not expanded at the same pace, and the resulting gap has created a saturated landscape in which product quality, documentation, and compliance posture vary considerably from one supplier to the next.
For a licensed clinician, selecting a placental or perinatal tissue products supplier is not merely a procurement decision. It is a compliance obligation that carries direct implications for patient safety, Food and Drug Administration (FDA) regulatory exposure, and state scope-of-practice adherence. This article delineates the regulatory baseline that governs human cells, tissues, and cellular and tissue-based products (HCT/Ps), the accreditation and documentation a diligent buyer should expect to see, and the red flags that pertain specifically to the placental and perinatal tissue category.
The regulatory baseline: 21 CFR Part 1271 and HCT/Ps
Placental and perinatal tissue products, including amniotic membrane, cord blood, and Wharton's Jelly derivatives, are regulated under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products. FDA guidance establishes two threshold criteria that determine whether a given product may be marketed solely under section 361 of the Public Health Service Act, without premarket approval: the tissue must be minimally manipulated, meaning processing does not alter the relevant biological characteristics of the tissue, and it must be intended for homologous use, meaning it performs the same basic function in the recipient that it performed in the donor [1]. A product that fails either criterion is regulated as a drug, biologic, or device, and requires an approved biologics license application or investigational new drug application before clinical use.
This distinction is imperative for clinicians to confront directly, rather than defer to a supplier's marketing claims. FDA has stated plainly that there are currently no FDA-approved placental or perinatal stem cell products for broad therapeutic indications outside of hematopoietic reconstitution [1]. A supplier that implies regenerative, anti-inflammatory, or disease-modifying claims for an unapproved product is marketing outside the bounds the agency permits, and the clinician who purchases and administers that product shares in the resulting regulatory and liability exposure.
Documentation every supplier should provide without hesitation
A compliant supplier of placental, cord blood, or Wharton's Jelly-derived products maintains, and should readily furnish, documentation across several domains. The absence of any one item below merits a direct follow-up question before purchase proceeds.
• Donor screening and consent records. Maternal donors must undergo risk-factor screening and communicable disease testing consistent with 21 CFR Part 1271 Subpart C, with documented informed consent on file at the tissue bank of origin.
• Facility registration. Tissue establishments that recover, process, or distribute HCT/Ps are required to register with FDA and list their products, a status that can be independently verified rather than taken on a supplier's word.
• Accreditation credentials. Accreditation through the American Association of Tissue Banks (AATB) is voluntary but widely regarded as the operative standard for tissue banking practice, covering donor eligibility, recovery, processing, and distribution [2].
• Current good manufacturing or tissue practice (cGMP/cGTP) evidence. Processing should occur under controlled, validated conditions, with batch-level processing records available for audit.
• Cell or tissue characterization data. **Reputable suppliers can produce viability, potency, or identity testing data specific to the lot being purchased, rather than generic marketing collateral.
State scope-of-practice considerations
Supplier vetting does not end with federal compliance. Many states, including Florida, impose licensure and scope-of-practice limits on which categories of practitioners may purchase, store, and administer human cellular products, and under what clinical circumstances. A clinician should confirm that a given product and its labeled use fall within the bounds of their professional license before purchase, independent of any assurance the supplier provides. This is a matter for qualified regulatory or healthcare counsel, not for a sales representative.
**A practical red-flag checklist for supplier vetting
Before finalizing a purchasing relationship with any placental or perinatal tissue products supplier, clinicians should confirm the following:
1. Donor screening and consent: the supplier cannot produce documentation of donor risk-factor screening, communicable disease testing, and informed consent for the tissue lot in question.
2. GMP-equivalent processing: processing facilities and methods are not disclosed, or the supplier declines to describe how lot-to-lot consistency is controlled.
3. Accreditation status: the supplier cannot name a current, verifiable AATB or equivalent accreditation, or offers only an expired or unconfirmed credential.
4. Scope-of-practice compliance: marketing materials suggest the product is appropriate for any licensed provider to administer, without qualification against state-specific scope-of-practice rules.
5. Cell characterization data availability: lot-specific viability, identity, or potency data is unavailable on request, leaving the buyer unable to verify what is actually being administered.
Any one of these gaps is a reason to pause the purchasing decision. Multiple gaps together indicate a supplier relationship that is unlikely to withstand regulatory scrutiny, and FDA has shown a sustained willingness to act against clinics and suppliers operating outside these parameters [4].
Where umbilical cord and Wharton's Jelly-derived products fit
Clinicians researching a placental stem cell products supplier should also evaluate umbilical cord and Wharton's Jelly-derived options, which sit within the same perinatal tissue category and are subject to the identical regulatory framework under 21 CFR Part 1271. Cord blood-derived hematopoietic stem cells and Wharton's Jelly mesenchymal stem cells are collected at the time of birth and processed under controlled conditions, with isolation performed through density gradient separation or immuno-selection methods. Published research on Wharton's Jelly-derived mesenchymal stem cells documents their immunomodulatory and proliferative characteristics, which continue to be studied across orthopedic, wound, and regenerative applications, though clinicians should treat such findings as an active area of investigation rather than an approved therapeutic claim [3].
Where RegenOMedix fits into this evaluation
RegenOMedix is a division of Zizion Group that distributes cord blood hematopoietic stem cells, Wharton's Jelly mesenchymal stem cells, and related exosome products to licensed clinicians, clinics, and distributors.
For practices conducting a formal vendor review, the full specification sheet for RegenOMedix's placental stem cell products supplier category, including the cord blood and Wharton's Jelly lines described above, is available for direct comparison against the checklist in this article.
RegenOMedixmaintains sourcing, processing, and documentation practices consistent with the standards outlined here, and welcomes the kind of credential review this article describes. This is a matter of matching documentation to the clinician's own compliance obligations, not a substitute for a clinician's own due diligence.
Licensed clinicians and distributors evaluating a supplier change, or seeking the underlying documentation referenced above, may contact RegenOMedix directly to request current accreditation and processing records.